Financial Results | Novartis 2025 Q3 Cumulative Revenue USD 42814.00 Million Net Income USD 11563.00 Million

Novartis(NVS) posted the Q3 of its 2025 financial results on 10/28/2025, reporting total revenue of USD 42814.00 million in the first three quarters, up 12.18% from USD 38164.00 million year over year, reporting net income of USD 11563.00 million in the first three quarters, up 26.80% from USD 9119.00 million year over year. The EPS is USD 5.94 in the first three quaters, compare with USD 4.5 last period.

[Detailed Data]

Million USD	Q3 2025	Q2 2025	Q1 2025	Q4 2024
Total Revenue	14358.00	14836.00	13620.00	13558.00
Cost of Sales	3539.00	3322.00	3227.00	3324.00
Gross Profit	10819.00	11514.00	10393.00	10234.00
Total Operating Expenses	6599.00	6939.00	6000.00	6979.00
Operating Income	4220.00	4575.00	4393.00	3255.00
Net Income	3930.00	4024.00	3609.00	2820.00
Net Income Attributable to Common Shareholders	3928.00	4041.00	3606.00	2818.00
EPS(USD)	2.04	2.07	1.83	1.4268

[Company Profile]
Novartis Ag was incorporated on February 29, 1996 under the laws of Switzerland as a stock corporation (Aktiengesellschaft) with an indefinite duration. The company is an innovative medicines company engaged in the research, development, manufacturing, distribution, marketing and sale of a broad range of innovative pharmaceutical medicines. The company's purpose is to reimagine medicine to improve and extend people's lives by leveraging their scientific expertise to find new ways to treat and cure disease. The company's operations are organized into five organizational units: Biomedical Research, Development, Operations, and two commercial units US and International. Global functions support these organizational units in the execution of their work. The company focus on four core therapeutic areas with strong growth potential and high unmet patient needs—cardiovascular, renal and metabolic; immunology; neuroscience; and oncology.